ICIs alone or in combination with chemotherapy have become standard-of-care treatment for NSCLC patients whose tumors express PDL1 and lack EGFR mutations or EML4/ALK rearrangements [94,95,96,97,98,99]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.